ADH7 Antibody

What is ADH7 and what biological functions does it serve?

ADH7 (Alcohol Dehydrogenase 7) is an enzyme that primarily catalyzes the NAD-dependent oxidation of all-trans-retinol, alcohol, and omega-hydroxy fatty acids and their derivatives. It preferentially oxidizes all trans-retinol, all-trans-4-hydroxyretinol, 9-cis-retinol, 2-hexenol, and long chain omega-hydroxy fatty acids such as juniperic acid. ADH7 can also catalyze the NADH-dependent reduction of all-trans-retinal and aldehydes in vitro, with greater efficiency in the oxidative direction. Physiologically, ADH7 participates in retinoid metabolism, fatty acid omega-oxidation, and elimination of cytotoxic aldehydes produced by lipid peroxidation .

What are the main types of ADH7 antibodies available for research?

Research-grade ADH7 antibodies are available in several formats, each with distinct characteristics:

• Rabbit Recombinant Monoclonal antibodies - Offer high specificity and consistency across batches, suitable for ICC/IF and Western blotting applications with human samples

• Rabbit Polyclonal antibodies - Recognize multiple epitopes of ADH7, applicable for Western blot and ELISA with human and monkey samples

• Mouse Monoclonal antibodies - Provide high specificity for a single epitope, useful for various biochemical applications

Each antibody type offers different advantages depending on the experimental design and research questions.

What applications are ADH7 antibodies typically used for?

ADH7 antibodies are employed in various molecular and cellular biology techniques including:

• Western Blotting (WB) - For detecting and quantifying ADH7 protein in tissue or cell lysates

• Immunocytochemistry/Immunofluorescence (ICC/IF) - For visualizing cellular localization of ADH7

• Enzyme-Linked Immunosorbent Assay (ELISA) - For quantitative detection of ADH7 in serum, plasma, or tissue homogenates

The selection of an appropriate application depends on the specific research question, sample type, and required sensitivity level.

How should I select the appropriate ADH7 antibody for my specific research application?

When selecting an ADH7 antibody, consider these critical factors:

• Target species compatibility - Ensure the antibody reacts with your species of interest (human, monkey, etc.)

• Application suitability - Verify the antibody has been validated for your intended application (WB, ICC/IF, ELISA)

• Antibody format - Consider whether monoclonal (higher specificity) or polyclonal (broader epitope recognition) better suits your needs

• Clonality and host species - Select based on compatibility with your detection system and other antibodies in multiplex experiments

• Validation data - Review available validation images and peer-reviewed publications using the antibody

For complex tissue samples or novel applications, preliminary testing of multiple antibodies may be necessary to determine optimal performance .

What are the optimal sample preparation methods for detecting ADH7 in different tissue types?

Sample preparation methods vary depending on the tissue type and downstream application:

For Western blotting:

• Homogenize tissues in RIPA buffer containing protease inhibitors

• For tissues with high lipid content (like stomach where ADH7 is expressed), include additional detergents

• Centrifuge at 10,000-14,000g for 15-20 minutes at 4°C to remove debris

• Determine protein concentration using Bradford or BCA assay

For ELISA:

• For serum/plasma: Collect in appropriate anticoagulant tubes and centrifuge promptly

• For tissue homogenates: Use specific ELISA-compatible lysis buffers that preserve the native protein structure

• Dilute samples appropriately within the detection range (0.312-20 ng/mL for human ADH7)

Sample storage at -80°C with minimal freeze-thaw cycles is recommended to preserve ADH7 epitope integrity.

How do I determine the optimal working dilution for ADH7 antibodies?

Determining optimal working dilution requires empirical testing:

• Begin with the manufacturer's recommended range (typically 1:500-1:2000 for Western blotting)

• Perform a dilution series experiment (e.g., 1:500, 1:1000, 1:2000, 1:5000)

• Evaluate signal-to-noise ratio, background levels, and specific band intensity

• For quantitative applications, ensure the signal falls within the linear detection range

• For reproducibility, standardize protein loading using housekeeping controls

As noted in the documentation: "Optimal working dilution should be determined by the investigator" . Consider that different applications may require different dilutions, even with the same antibody.

How can ADH7 antibodies be employed to study retinoid metabolism pathways?

ADH7 plays a critical role in retinoid metabolism, particularly in the oxidation of all-trans-retinol to retinal. Researchers can use ADH7 antibodies to:

• Map expression patterns - Use immunohistochemistry to identify tissues with high ADH7 expression, correlating with retinoid processing capabilities

• Co-immunoprecipitation studies - Investigate ADH7 interactions with other components of the retinoid metabolism pathway

• Activity modulation experiments - Combine with functional assays to correlate ADH7 protein levels with retinol oxidation activity

• Subcellular localization - Employ immunofluorescence microscopy to determine compartmentalization of ADH7 in relation to retinoid processing organelles

These approaches can reveal how ADH7 contributes to retinoid homeostasis, particularly in tissues where specific retinoid metabolites drive cellular differentiation and function .

What methodologies can be used to investigate ADH7's role in detoxification of lipid peroxidation aldehydes?

To study ADH7's role in detoxifying aldehydes produced during lipid peroxidation:

• Oxidative stress models - Use Western blotting to quantify ADH7 upregulation in response to oxidative challenges

• Enzyme activity correlation - Combine immunoblotting for ADH7 with enzymatic assays measuring aldehyde reduction

• Knockdown/knockout approaches - Use siRNA or CRISPR with ADH7 antibodies to verify protein reduction and correlate with cellular sensitivity to aldehyde toxicity

• Mass spectrometry integration - Use immunoprecipitation with ADH7 antibodies to isolate enzyme complexes, followed by MS analysis to identify aldehyde substrates

• In vitro substrate specificity - Employ purified ADH7 (verified by antibodies) for enzyme kinetics with various aldehyde substrates

This multi-faceted approach can elucidate ADH7's protective role against oxidative stress damage and cytotoxic aldehydes .

How can multiplex assays be designed to study ADH7 in relation to other alcohol dehydrogenase family members?

Designing multiplex assays to study ADH7 alongside other ADH family members requires careful consideration:

• Antibody selection - Choose antibodies raised in different host species (e.g., rabbit anti-ADH7, mouse anti-ADH1) to allow simultaneous detection

• Fluorophore selection - Use spectrally distinct fluorophores for each secondary antibody to avoid signal overlap

• Cross-reactivity testing - Validate that each primary antibody doesn't cross-react with other ADH family members

• Sequential immunoblotting - For Western blots, use sequential stripping and reprobing with antibodies against different ADH isoforms

• Multiplex ELISA development - Design custom assays with capture antibodies specific to different ADH isoforms

This approach enables comparative analysis of expression patterns, revealing tissue-specific distribution of ADH isoforms and potentially identifying compensatory mechanisms in ADH7-deficient models.

What are common pitfalls when using ADH7 antibodies for Western blotting, and how can they be addressed?

Common challenges with ADH7 detection by Western blotting include:

To verify specificity, use appropriate positive controls (tissues known to express ADH7) and negative controls (tissues or cell lines with minimal ADH7 expression).

How can researchers optimize ADH7 detection sensitivity in ELISA assays?

To maximize ADH7 detection sensitivity in ELISA:

• Sample preparation optimization:

  • Process samples immediately after collection

  • Use protease inhibitors to prevent degradation

  • Determine appropriate dilution to fall within the standard curve range (0.312-20 ng/mL)

• Assay execution refinements:

  • Strictly adhere to incubation times (2 hours for samples, 1 hour for detection reagents)

  • Maintain consistent temperature (37°C) throughout incubation steps

  • Perform thorough washing between steps (minimum 3-5 washes)

  • Optimize substrate development time (15-25 minutes) based on signal intensity

• Technical considerations:

  • Use freshly prepared standards for each assay

  • Pre-warm all reagents to room temperature before use

  • Consider signal amplification systems for ultra-sensitive detection

  • Validate results across multiple sample dilutions to confirm linearity

These optimizations can significantly improve the lower detection limit beyond the standard 0.312 ng/mL threshold .

What strategies can address cross-reactivity issues with ADH7 antibodies?

Cross-reactivity with other ADH family members presents a significant challenge due to sequence homology. To address this:

• Antibody selection strategies:

  • Choose antibodies raised against unique regions of ADH7

  • Consider recombinant monoclonal antibodies for higher specificity

  • Review validation data showing absence of cross-reactivity

• Experimental validation approaches:

  • Test antibodies on recombinant ADH isoforms expressed in heterologous systems

  • Include knockout/knockdown controls to confirm specificity

  • Perform peptide competition assays to demonstrate epitope specificity

• Advanced verification methods:

  • Perform immunoprecipitation followed by mass spectrometry to confirm antibody targets

  • Use orthogonal detection methods to corroborate findings

  • In multiplexed analyses, include isoform-specific controls

These approaches collectively enhance confidence in the specificity of detected signals.

How should researchers interpret contradictory results from different ADH7 antibody clones?

When faced with contradictory results from different ADH7 antibody clones:

• Compare antibody characteristics:

  • Identify the epitopes recognized by each antibody (N-terminal, C-terminal, internal)

  • Consider clonality differences (polyclonal vs. monoclonal)

  • Review validation methods used by manufacturers

• Perform technical validation:

  • Test antibodies side-by-side under identical conditions

  • Include positive controls (tissues known to express ADH7)

  • Use genetic approaches (siRNA knockdown) to confirm specificity

• Consider biological explanations:

  • Different epitopes may be differentially accessible due to protein folding or post-translational modifications

  • Some antibodies may detect specific ADH7 isoforms or splice variants

  • Protein complexes may mask epitopes in certain cellular contexts

• Resolution strategies:

  • Use complementary techniques (e.g., mass spectrometry) for verification

  • Report findings transparently, acknowledging antibody-specific differences

  • Consider the possibility that both results reflect biological reality from different perspectives

This systematic approach helps resolve apparent contradictions in experimental outcomes.

What considerations are important when quantifying ADH7 expression levels across different tissue types?

When quantifying ADH7 expression across diverse tissues:

• Sample standardization:

  • Normalize to total protein content rather than specific housekeeping genes, which may vary across tissues

  • Consider tissue-specific extraction efficiencies and adjust protocols accordingly

  • Use consistent sample processing methods across all tissues

• Technical normalization:

  • Include recombinant ADH7 standards at known concentrations

  • Apply appropriate standard curves for each experiment

  • Account for tissue-specific matrix effects that may influence detection

• Biological considerations:

  • Acknowledge that ADH7 expression is naturally higher in certain tissues (e.g., gastric mucosa)

  • Consider developmental and pathological states that might alter expression

  • Account for potential post-translational modifications affecting antibody binding

• Validation approaches:

  • Correlate protein detection with mRNA quantification

  • Use multiple antibodies targeting different epitopes

  • Verify with enzymatic activity assays where possible

These considerations enable meaningful comparisons of ADH7 expression between different tissue types.

How can researchers distinguish between active and inactive forms of ADH7 using antibody-based approaches?

Distinguishing active from inactive ADH7 forms requires sophisticated approaches:

• Phosphorylation-specific antibodies:

  • Develop or source antibodies specifically recognizing phosphorylated ADH7 at regulatory sites

  • Use phosphatase treatments as controls to confirm specificity

• Conformation-sensitive detection:

  • Employ antibodies that preferentially bind the NAD+-bound (active) conformation

  • Use native versus denatured Western blotting to preserve structural information

• Activity correlation studies:

  • Combine immunoprecipitation using ADH7 antibodies with activity assays

  • Correlate protein levels detected by Western blot with enzymatic activity measurements

• Subcellular localization analysis:

  • Use immunofluorescence to track ADH7 translocation associated with activation

  • Correlate localization with known activation states

• Co-immunoprecipitation approaches:

  • Identify interaction partners that bind specifically to active ADH7

  • Use antibodies to co-precipitate these complexes

These approaches help researchers move beyond simple expression analysis to functional assessment of ADH7 activity states.

What are the key differences between using ADH7 antibodies for basic research versus clinical diagnostic applications?

Comparing research and potential diagnostic applications reveals important distinctions:

While research applications benefit from diverse approaches, diagnostic use would require rigorous standardization and validation processes beyond current evidence for ADH7 antibodies .

How do monoclonal and polyclonal ADH7 antibodies compare in challenging research applications?

A comparative analysis of monoclonal versus polyclonal ADH7 antibodies reveals distinct advantages:

For ADH7 research, recombinant monoclonal antibodies offer the advantages of both approaches—high specificity with consistent reproducibility .

What are effective strategies for validating novel ADH7 antibodies for research applications?

Comprehensive validation of novel ADH7 antibodies should include:

• Specificity validation:

  • Test on overexpression systems (cells transfected with ADH7)

  • Validate on knockout/knockdown models

  • Perform peptide competition assays

  • Test cross-reactivity with other ADH family members

• Application-specific validation:

  • For Western blotting: Confirm correct molecular weight (41.5 kDa)

  • For ICC/IF: Verify expected subcellular localization

  • For ELISA: Establish standard curves with recombinant protein

• Biologically relevant validation:

  • Test on tissues known to express ADH7 (gastric mucosa)

  • Verify detection in appropriate species (human, monkey)

  • Confirm consistency with literature-reported expression patterns

• Technical performance assessment:

  • Determine sensitivity limits

  • Establish reproducibility across multiple experiments

  • Evaluate stability under various storage conditions

Documentation of these validation steps enables confident application of novel antibodies in ADH7 research.